Globeimmune Inc., of Louisville, Colo., reported data from 11 chordoma patients in its phase I trial of GI-6301 at the Connective Tissue Oncology Society meeting in Berlin, showing the Tarmogen candidate, a yeast-brachyury vaccine, was generally well tolerated, immunogenic and showed evidence of clinical activity in both advanced epithelial cancers and chordomas.